At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
In this study, researchers want to see if enzalutamide, alone or with mifepristone, works well against advanced breast cancer. The people in this study have either triple-negative breast cancer (TNBC) or cancer that is low in estrogen receptors (ER). Receptors are docking sites on cancer cells for hormones or other proteins. TNBC is breast cancer that is not fueled by estrogen or progesterone and does not make a protein called HER2. The people in this study also have cancer cells that have receptors for proteins called androgens (AR-positive cancers).
-
Researchers want to find the best dose of AZD0754 for people with prostate cancer. The patients in this study have prostate cancer that has metastasized (spread).
-
Plasmablastic lymphoma is a type of B-cell non-Hodgkin lymphoma (NHL). The purpose of this study is to determine if adding daratumumab to a standard chemotherapy regimen (DA-EPOCH) is a safe way to increase the effectiveness of treatment in people with plasmablastic lymphoma.   
-
The purpose of this study is to assess the effectiveness of adding apalutamide, abiraterone acetate, and prednisone to the usual hormone therapy and radiation therapy for patients who have a recurrence of their prostate cancer after surgery (prostatectomy). Specifically, there must have been cancer originally found in the lymph nodes at the time of surgery for patients to be eligible for this study. The treatment being evaluated is a "salvage therapy" for recurrent prostate cancer. Patients will be randomly assigned to receive hormone therapy and radiation therapy after prostate cancer surgery with or without apalutamide, abiraterone acetate, and prednisone. 
-
Researchers want to see if the herbal supplement Ma-Zi-Ren-Wan (MZRW) helps relieve chronic constipation in survivors of cancer. They will also see how MZRW affects the gut microbiome.
-
V940 is made in a laboratory. It uses genes in your cancer to teach your immune system to fight the cancer. V940 is given as an injection into a muscle. Pembrolizumab boosts the ability of the immune system to find and kill cancer cells. It is given intravenously (by vein).
-
Researchers want to see if giving additional radiation therapy to standard treatment helps people with lung cancer to live longer. The people in this study have non-small cell lung cancer (NSCLC) that cannot be removed with surgery (inoperable cancer). The standard treatment includes image-guided radiation therapy (IGRT), chemotherapy, and immunotherapy with durvalumab. 
- A Phase 1 Study of IMA203 Cellular Therapy With mRNA-4203 in People With Cutaneous Melanoma or Synovial Sarcoma
Full Title A First-in-Human, Open-Label Trial to Evaluate the Combination of ACTengineTM IMA203 with mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengineTM IMA203-102)
Purpose
Researchers are seeking the best dose of mRNA-4203 to give with a cellular therapy in people with melanoma or sarcoma. The cellular therapy is called IMA203 and is custom-made from each patient’s white blood cells.
The people in this study have melanoma or synovial sarcoma that metastasized (spread) or is inoperable (cannot be surgically removed). In addition, their cancers have a protein called HLA-A*02:01.
IMA203 is made from T cells, which protect the body from infections, cancer, and other possible harms. Some cancers can block T cells from attacking cancer cells. We will collect some of your T cells and change them to help them find and kill your cancer cells. These modified T cells are called TCR (T cell receptor)-engineered T cells. Treatments made from them are called TCR T-cell therapies.
mRNA-4203 is a vaccine that may help activate the immune system to better target and kill cancer cells.
Who Can Join
To join this study, there are a few conditions. You must:
- Have HLA-A*02:01-positive metastatic or inoperable melanoma of the skin or synovial sarcoma.
- Have recovered from the serious side effects of previous treatments before getting the study therapy.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. James Smithy’s office at 646-888-6782.
Protocol
25-223Phase
Phase I (phase 1)Disease Status
Newly Diagnosed & Relapsed/RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06946225ClinicalTrials.gov
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
The purpose of this study is to compare the safety and effectiveness of adding duvelisib or CC-486 (oral azacitidine) to the usual chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) in people with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth; it is taken orally (by mouth).